iShares Russell 2000 ETF (IWM)

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

Small-cap stocks have historically outperformed their bigger siblings, and there are three reasons 2026 could see that trend reassert itself.

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

Several Wall Street firms moved quickly to reset expectations, citing limited upside now that the stock trades close to the proposed buyout price.

The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation," investors are pulling capital from the expensive, AI-saturated titans of the Nasdaq and pouring